
Moderna’s melanoma vaccine shows promise despite stock plunge
The story in brief
A personalized mRNA vaccine for late-stage melanoma showed promise in reducing cancer recurrence, with side effects similar to Covid vaccines. However, investors reacted negatively to leaked findings, causing Moderna’s stock to drop. Results will be presented at the European Society for Medical Oncology meeting in Madrid.